Unknown

Dataset Information

0

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.


ABSTRACT: 1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52) showed a 7-fold increase in potency, a 65-fold increase in C(max), and a 3300-fold increase in AUC over its adamantane analogue 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea (2). This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mechanical withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.

SUBMITTER: Rose TE 

PROVIDER: S-EPMC3285450 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Rose Tristan E TE   Morisseau Christophe C   Liu Jun-Yan JY   Inceoglu Bora B   Jones Paul D PD   Sanborn James R JR   Hammock Bruce D BD  

Journal of medicinal chemistry 20101001 19


1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52)  ...[more]

Similar Datasets

| S-EPMC9850727 | biostudies-literature
| S-EPMC2900318 | biostudies-literature
| S-EPMC3541548 | biostudies-literature
| S-EPMC3596469 | biostudies-literature
| S-EPMC3372725 | biostudies-literature
| S-EPMC5417501 | biostudies-literature
| S-EPMC8877601 | biostudies-literature
| S-EPMC3517215 | biostudies-literature
| S-EPMC4834590 | biostudies-literature
| S-EPMC9051153 | biostudies-literature